Infliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)

Size: px
Start display at page:

Download "Infliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)"

Transcription

1 Infliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 01/01/201810/01/2016TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy. REMICADE FDA-Approved Indications Moderately to severely active Crohn s disease in adults and pediatric patients Moderately to severely active ulcerative colitis in adults and pediatric patients Moderately to severely active rheumatoid arthritis in combination with methotrexate Active ankylosing spondylitis Active psoriatic arthritis Chronic severe plaque psoriasis in adults Compendial Uses Axial spondyloarthritis Behçet s syndrome Granulomatosis with polyangiitis (Wegener s granulomatosis) Hidradenitis suppurativa Juvenile idiopathic arthritis Pyoderma gangrenosum Sarcoidosis Takayasu s arteritis Uveitis INFLECTRA AND RENFLEXIS FDA-Approved Indications Moderately to severely active Crohn s disease in adults and pediatric patients

2 InfliximabRemicade 2 Moderately to severely active ulcerative colitis in adults Moderately to severely active rheumatoid arthritis in combination with methotrexate Active ankylosing spondylitis Active psoriatic arthritis Chronic severe plaque psoriasis in adults Compendial Uses None B. REQUIRED DOCUMENTATION The following information is necessary to initiate the prior authorization review: For psoriasis, the following documentation is required: o For new starts on therapy Documentation supporting a history of plaque psoriasis for longer than six months Percent of body surface area involvement Results of treatment with methotrexate such as ineffective treatment or intolerance, or documentation that methotrexate is contraindicated o For continuation of therapy, documentation in member s chart or medical record supporting a decrease in percent of body surface area involvement when compared to baseline must be submitted For Crohn s disease, prescribers will be asked to fill in the member s Crohn s Disease Activity Index (CDAI) at baseline and after 6 months of therapy C. CRITERIA FOR INITIAL APPROVAL 1. Moderately to severely active Crohn s disease (CD) Initial authorization for 6 months may be granted for members who meet the following criteria: i. Member has a pre-treatment Crohn s Disease Activity Index (CDAI) score 220, OR ii. iii. Member has fistulizing disease, AND Member has tried any of the following conventional therapies for CD: mesalamine, sulfasalazine, ciprofloxacin, metronidazole, azathioprine, mercaptopurine, methotrexate, methylprednisolone, or prednisone. 2. Moderately to severely active ulcerative colitis (UC) Initial authorization for 6 months may be granted for members who meet both of the following criteria: i. Member has moderately to severely active UC ii. Member has tried any of the following conventional therapies for UC: mesalamine, sulfasalazine, azathioprine, mercaptopurine, methylprednisolone, prednisone, cyclosporine, tacrolimus (or antibiotics for pouchitis only). 3. Moderately to severely active rheumatoid arthritis (RA) Initial authorization of 6 months may be granted for members with RA who meet the following criteria: i. Member has tried a disease modifying anti-rheumatic drug (DMARD) ii. RemicadeInfliximab must be prescribed in combination with methotrexate or leflunomide unless the member has a clinical reason not to use methotrexate or leflunomide

3 InfliximabRemicade 3 4. Moderate to severe chronic plaque psoriasis Initial authorization of 6 months may be granted for members who meet ALL of the following criteria: i. Treatment with Remicadeinfliximab was recommended by a dermatologist ii. Member has been diagnosed with moderate to severe chronic plaque psoriasis defined as the following a) At least 10% of body surface area (BSA) is affected, or crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected, and b) History of psoriasis 6 months or longer iii. iv. Plaque psoriasis is characterized by well-defined patches of red and raised skin Member has tried methotrexate for at least 3 months at a therapeutic dose and found it to be ineffective, or the member exhibited intolerance or allergy, or the use of methotrexate is contraindicated. a) Ineffective treatment is defined as symptoms and/or signs that are not resolved after completion of treatment at the recommended therapeutic dose and duration. If there is no recommended treatment time, the member must have had a meaningful trial. b) Intolerance is defined as having a recognized and reproducible or repeated adverse reaction that is clearly associated with taking the medication. c) Allergy is defined as a state of hypersensitivity produced by exposure to a particular antigen resulting in harmful immunologic reactions on subsequent exposures. The most common symptoms are skin rash or anaphylaxis. 5. Active psoriatic arthritis (PsA) Initial authorization of 6 months may be granted for members who meet the following criteria: i. Member has been diagnosed with active PsA, and meets ANY of the following: a) Member experienced an inadequate response to methotrexate. b) Member has a history of intolerance to methotrexate. c) Member has a contraindication to methotrexate. 6. Active ankylosing spondylitis (AS) and axial spondyloarthritis* Initial authorization of 6 months may be granted for members with active AS/axial spondyloarthritis* who meet ANY of the following criteria: i. Member has experienced an inadequate response to treatment with an NSAID over a 4- week period in total at the maximum recommended or tolerated anti-inflammatory dose ii. Member has experienced intolerance to NSAID therapy iii. Member has a contraindication to all NSAIDs * Axial spondyloarthritis is a covered indication for Remicade only. 7. Active polyarticular juvenile idiopathic arthritis (pjia) (covered indication for Remicade only) Initial authorization of 6 months may be granted for members with active pjia who have tried a disease modifying anti-rheumatic drug (DMARD). 8. Hidradenitis suppurativa (covered indication for Remicade only) Initial authorization of 6 months may be granted for members who have severe hidradenitis suppurative that is refractory to standard first-line treatment (eg, antibiotics). 9. Behçet s syndrome (covered indication for Remicade only)

4 InfliximabRemicade 4 treatment of Behçet s syndrome. 10. Granulomatosis with polyangiitis (Wegener s granulomatosis) (covered indication for Remicade only) treatment of granulomatosis with polyangiitis. 11. Pyoderma gangrenosum (covered indication for Remicade only) treatment of pyoderma gangrenosum. 12. Sarcoidosis (covered indication for Remicade only) treatment of sarcoidosis. 13. Takayasu s arteritis (covered indication for Remicade only) treatment of Takayasu s arteritis. 14. Uveitis (covered indication for Remicade only) treatment of uveitis. D. CONTINUATION OF THERAPY No previous authorization/precertification: All members (including members currently receiving treatment without prior authorization) must meet criteria for initial approval in section C. Members who are continuing with Remicade treatment are subject to the continuation criteria below for approval. Members who are starting treatment with Remicade are required to meet criteria for initial authorization in section C. above. Reauthorization: Authorization may be granted to members requesting authorization for continuation of therapy if infliximab was previously authorized by HMSA/CVS and the criteria below are met. Chronic plaque psoriasis To receive authorization for an additional 6 months of therapy for chronic plaque psoriasis, documentation supporting a decrease in percent of body surface area involvement when compared to baseline must be submitted. Thereafter, authorization of 12 months may be granted. Crohn s disease For members receiving 6 to 12 months of treatment with Remicadeinfliximab, a positive clinical response to treatment as evidenced by a decreased or stable CDAI score compared with baseline is required. Thereafter, authorization of 12 months may be granted. All other indications

5 InfliximabRemicade 5 Authorization of 12 months may be granted for members who achieve or maintain positive clinical response as evidenced by low disease activity, improvement in signs and symptoms or maintenance of improvement in signs and symptoms. E. DOSAGE AND ADMINISTRATION Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. F. ADMINISTRATIVE GUIDELINES Prior authorization is required. Please refer to the HMSA medical policy web site for the fax form. G. IMPORTANT REMINDER The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician. Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii s Patients Bill of Rights and Responsibilities Act (Hawaii Revised Statutes 432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA s determination as to medical necessity in a given case, the physician may request that CVS/caremark reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation. H. REFERENCES 1. Remicade [package insert]. Horsham, PA: Janssen Biotech, Inc.; October van der Heijde D, Sieper J, Maksymowych WP, et al Update of the international ASAS recommendations for the use of anti-tnf agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70: DRUGDEX System (electronic version). Truven Health Analytics, Ann Arbor, MI. Available at Accessed September 24, 2014May 24, Talley NJ, Abreu MT, Achkar J, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(Suppl 1):S2-S Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6): Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73: Singh JA, Furst DE, Bharat A, et al Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):

6 InfliximabRemicade 6 8. Aletasha D, Neogi T, Silman AJ, et al Rheumatoid Arthritis Classification Criteria. An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010;62: Anderson J, Caplan L, Yazdany J, et al. Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice. Arthritis Rheum. 2010;64: Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1): Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71: Gladman DD, Antoni C, P Mease, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl II):ii14 ii Peluso R, Lervolino S, Vitiello M, et al. Extra-articular manifestations in psoriatic arthritis patients. Clin Rheumatol May 8. [Epub ahead of print]. 14. Braun J, van den Berg R, Baraliakos X, et al update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70: Beukelman T, Patkar NM, Saag KG, et al American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63(4): Ringold S, Weiss PF, Beukelman T, et al Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. Arthritis & Rheumatism. 2013;65: Inflectra [package insert]. New York, NY: Pfizer, Inc.; August Renflexis [package insert]. Incheon, South Korea: Samsung Bioepsis Co Ltd; April Revised: September Document History 10/01/2015 Original CVS/HMSA effective date 09/2016 Annual review 05/2017 Annual review; added Inflectra and Renflexis TBD Revision effective date

Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration. Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018

Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration. Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018 Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018 POLICY A. INDICATIONS The indications below including

More information

Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)

Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) DRUG POLICY BENEFIT APPLICATION Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Benefit determinations are based on the applicable contract language in effect at the time

More information

Remicade (infliximab)

Remicade (infliximab) Remicade (infliximab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda) RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic

More information

Cimzia (certolizumab pegol)

Cimzia (certolizumab pegol) DRUG POLICY BENEFIT APPLICATION Cimzia (certolizumab pegol) Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations

More information

POLICY Document for REMICADE

POLICY Document for REMICADE POLICY Document for REMICADE The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific to use of preferred medication options, lower cost site

More information

Amjevita (adalimumab-atto)

Amjevita (adalimumab-atto) *- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease

More information

Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)

Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subject: Infliximab Page: 1 of 13 Last Review Date: December 8, 2017 Infliximab Description Remicade

More information

Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis

More information

Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form Submit request via: Fax

Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form  Submit request via: Fax Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Humira (adalimumab) require a prior

More information

Remicade (Infliximab)

Remicade (Infliximab) Remicade (Infliximab) Policy Number: Original Effective Date: MM.04.016 11/18/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/26/2013 Section: Prescription Drugs Place(s)

More information

C. Assess clinical response after the first three months of treatment.

C. Assess clinical response after the first three months of treatment. Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit

More information

Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form Submit request via: Fax

Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form   Submit request via: Fax Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Enbrel (etanercept) require a prior

More information

Clinical Policy: Etanercept (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Etanercept (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If

More information

Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64

Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64 Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG.00002 CG-DRUG-64 Override(s) Prior Authorization *Washington Medicaid See State Specific Mandates Medications Inflectra

More information

PHARMACY POLICY STATEMENT Ohio Medicaid

PHARMACY POLICY STATEMENT Ohio Medicaid DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Ohio Medicaid Enbrel (etanercept) Must use

More information

ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid

More information

Infliximab/Infliximab-dyyb DRUG.00002

Infliximab/Infliximab-dyyb DRUG.00002 Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date:

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date: Clinical Policy: (Cimzia) Reference Number: ERX.SPA.167 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date:

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date: Clinical Policy: (Cimzia) Reference Number: ERX.SPA.167 Effective Date: 1.1.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Carelirst.+.V Family of health care plans

Carelirst.+.V Family of health care plans Carelirst.+.V Family of health care plans CVS Caremark POLICY Document for ACTEMRA The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific

More information

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

More information

Pharmacy Medical Necessity Guidelines:

Pharmacy Medical Necessity Guidelines: Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

Somatuline Depot (lanreotide)

Somatuline Depot (lanreotide) Somatuline Depot (lanreotide) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications

More information

Clinical Policy: Infliximab (Remicade) and Infliximab-dyyb (Inflectra) Reference Number: CP.PHAR.254

Clinical Policy: Infliximab (Remicade) and Infliximab-dyyb (Inflectra) Reference Number: CP.PHAR.254 Clinical Policy: Infliximab (Remicade) and Infliximab-dyyb (Inflectra) Reference Number: CP.PHAR.254 Effective Date: 07/16 Last Review Date: 12/16 See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Infliximab (Remicade), Infliximab-dyyb (Inflectra), and Infliximab-abda (Renflexis) Reference Number: ERX.SPA.160 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1041-8 Program Prior Authorization/Notification Medication Humira (adalimumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,

More information

Remicade (infliximab) DRUG.00002

Remicade (infliximab) DRUG.00002 Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous

More information

Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254

Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254 Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end

More information

Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65

Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Market DC Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPMN.24

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPMN.24 Clinical Policy: (Cimzia) Reference Number: ERX.SPMN.24 Effective Date: 10/2016 Last Review Date: 12/2016 Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

Orencia (abatacept) DRUG.00040

Orencia (abatacept) DRUG.00040 Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28

More information

Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab)

Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab) Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab) Effective: November 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi

More information

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254 Effective Date: 07.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab_remicade 5/2002 2/2017 2/2018 2/2017 Description of Procedure or Service Infliximab (REMICADE

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Actemra) Reference Number: HIM.PA.SP32 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at

More information

Humira (adalimumab) DRUG.00002

Humira (adalimumab) DRUG.00002 Humira (adalimumab) DRUG.00002 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Humira 10 mg/0.2 ml syringe Humira pediatric Crohn s Disease starter pack 40 mg/0.8 ml

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:

Clinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Pharmacy Prior Authorization

Pharmacy Prior Authorization Pharmacy Prior Authorization MERC CARE PLA (MEDICAID) Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax

More information

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits. Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically

More information

Circle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4.

Circle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4. 06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Humira (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign

More information

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year

More information

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date: Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Pharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol)

Pharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol) Pharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol) Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has

More information

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N 12/21/2016 Prior Authorization Aetna Better Health of West Virginia Humira (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and

More information

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior

More information

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description

Remicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),

More information

Pharmacy Prior Authorization

Pharmacy Prior Authorization Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release)

Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Market DC Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Override(s) Prior Authorization Quantity Limit Medications Xeljanz (tofacitinib) Approval Duration 1 year Quantity Limit May be

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254 Effective Date: 07.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Infliximab, Infliximab-dyyb, Infliximab-abda File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab 5/2002 2/2018 2/2019 7/2018 Description of Procedure

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber

More information

First Name. Specialty: Fax. First Name DOB: Duration:

First Name. Specialty: Fax. First Name DOB: Duration: Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:

More information

Subject: Remicade (Page 1 of 5)

Subject: Remicade (Page 1 of 5) Subject: Remicade (Page 1 of 5) Objective: I. To ensure that Health Share/Tuality Health Alliance (THA) has a process by which the appropriate utilization of Remicade (Infliximab) for members whose diagnosis

More information

Carefirst.+.V Family of health care plans

Carefirst.+.V Family of health care plans Carefirst.+.V Family of health care plans CVS care mark POLICY Document for ENTYVIO The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific

More information

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

3. Has the patient shown improvement in signs and symptoms of the disease? Y N Pharmacy Prior Authorization MERC CARE (MEDICAID) Renflexis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254 Effective Date: 07.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY Remicade (Infliximab) MP-026-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Annual Approval Date: 9/17/2017 Revision

More information

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Cosentyx, Cosentyx Sensoready) Reference Number: HIM.PA.SP29 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See

More information

1. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA)?

1. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA)? Humira (adalimumab) Medication Request Form (MRF) for Healthy Indiana Plan (HIP) and Hoosier Healthwise (HHW) FAX TO: (858) 790-7100 c/o MedImpact Healthcare Systems, Inc. Attn: Prior Authorization Department

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Simponi, Simponi Aria Applicable Medical Benefit x Effective: 2/13/18 Pharmacy- Formulary 1 x Next Review: 12/18 Pharmacy- Formulary 2 x Date of Origin: 7/2010 Pharmacy- Formulary 3/Exclusive x Review

More information

Inflectra Frequently Asked Questions

Inflectra Frequently Asked Questions Inflectra Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Earlier in 2016, Inflectra (infliximab) was added to the Ontario Drug Benefit (ODB) Formulary as a Limited

More information

Dupixent (dupilumab)

Dupixent (dupilumab) Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Clinical Policy: Adalimumab (Humira) Reference Number: CP.PHAR.242 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Adalimumab (Humira) Reference Number: CP.PHAR.242 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Humira) Reference Number: CP.PHAR.242 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other GOLIMUMAB SIMPONI 22533, 22536, 34697, 35001 ROUTE = SUBCUTANE. GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a

More information

Cyramza (ramucirumab)

Cyramza (ramucirumab) Cyramza (ramucirumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 03/01/2017TBD03/01/2018 POLICY A. INDICATIONS The indications

More information

Medication Prior Authorization Form

Medication Prior Authorization Form Remicade (Infliximab) Policy Number: 1051 Policy History Approve Date: 12/11/2015 Revise Dates: Next Review: 12/11/2016 Review Dates: Preauthorization All Plans Benefit plans vary in coverage and some

More information

2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N

2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N Pharmacy Prior Authorization AETA BETTER HEALTH LOUISIAA (MEDICAID) Remicade (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign

More information

Clinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date:

Clinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date: Clinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy

More information

Perjeta (pertuzumab)

Perjeta (pertuzumab) Perjeta (pertuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201809/16/2018 POLICY A. INDICATIONS The indications

More information

Clinical Policy: Adalimumab (Humira) Reference Number: CP.PHAR.242 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Adalimumab (Humira) Reference Number: CP.PHAR.242 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Humira) Reference Number: CP.PHAR.242 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date:

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date: Clinical Policy: (Stelara) Reference Number: ERX.SPA.01 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:

Clinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date: Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPMN.167

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPMN.167 Clinical Policy: (Stelara) Reference Number: ERX.SPMN.167 Effective Date: 10/16 Last Review Date: 12/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Cimzia (Certolizumab pegol) - for Ankylosing Spondylitis, Crohn s Disease, Psoriatic Arthritis and Rheumatoid Arthritis POLICY NUMBER: PHARMACY-07 EFFECTIVE DATE: 5/2009 LAST REVIEW DATE: 6/13/2018

More information

Torisel (temsirolimus)

Torisel (temsirolimus) Torisel (temsirolimus) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 11/1/2017 POLICY A. INDICATIONS The indications below

More information

Clinical Policy: Anakinra (Kineret) Reference Number: ERX.SPA.135 Effective Date:

Clinical Policy: Anakinra (Kineret) Reference Number: ERX.SPA.135 Effective Date: Clinical Policy: (Kineret) Reference Number: ERX.SPA.135 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 12/30/201601/01/2018TBD03/01/2018 POLICY A. INDICATIONS The indications

More information

Velcade (bortezomib)

Velcade (bortezomib) Velcade (bortezomib) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 03/09/2004 Current Effective Date: 05/01/2017 POLICY A. INDICATIONS The indications below

More information

Regulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 10 Last Review Date: June 22, 2017 Humira Description Humira (adalimumab),

More information

Title: Remicade Biosmiliar Step Therapy Division: Medical Management Department: Utilization Management

Title: Remicade Biosmiliar Step Therapy Division: Medical Management Department: Utilization Management Retired Date: Page 1 of 5 1. POLICY DESCRIPTION: Step Therapy Requirement for Remicade (J1745); trial with biosimilar Inflectra (Q5103) or Renflexis (Q5104). 2. RESPONSIBLE PARTIES: Medical Management

More information

Xolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria.

Xolair (omalizumab) Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria. Xolair (omalizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 12/01/2017TBD POLICY A. INDICATIONS The indications below

More information

Gazyva (obinutuzumab)

Gazyva (obinutuzumab) Gazyva (obinutuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201807/01/2018 POLICY A. INDICATIONS The indications

More information

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next

More information